Kyle Diamantas leads trader consensus at 42.5% as the acting FDA commissioner following Marty Makary’s May 2026 resignation, drawing support from his role as deputy commissioner for human foods, prior Jones Day regulatory work, and reported ties to the Trump family amid the administration’s “Make America Healthy Again” priorities. Sara Brenner, Brett Giroir, Grace Graham, and Stephen Hahn trail as the White House weighs candidates with Senate confirmation hurdles, including requirements for medical or scientific credentials and positions on issues like mifepristone. The 21.4% probability of no permanent announcement by year-end reflects the ongoing search timeline, acting leadership stability, and potential delays from congressional reviews ahead of midterms.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoKyle Diamantas 41%
No announcement by December 31 21.4%
Sara Brenner 18.0%
Brett Giroir 15.0%
$12,400 Vol.
$12,400 Vol.
31 dic 2026
Kyle Diamantas
48%
Stephen Hahn
5%
Brett Giroir
11%
Grace Graham
7%
Sara Brenner
17%
No announcement by December 31
21%
Kyle Diamantas 41%
No announcement by December 31 21.4%
Sara Brenner 18.0%
Brett Giroir 15.0%
$12,400 Vol.
$12,400 Vol.
31 dic 2026
Kyle Diamantas
$2,472 Vol.
48%
Stephen Hahn
$1,491 Vol.
5%
Brett Giroir
$2,410 Vol.
11%
Grace Graham
$3,416 Vol.
7%
Sara Brenner
$2,021 Vol.
17%
No announcement by December 31
$590 Vol.
21%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads trader consensus at 42.5% as the acting FDA commissioner following Marty Makary’s May 2026 resignation, drawing support from his role as deputy commissioner for human foods, prior Jones Day regulatory work, and reported ties to the Trump family amid the administration’s “Make America Healthy Again” priorities. Sara Brenner, Brett Giroir, Grace Graham, and Stephen Hahn trail as the White House weighs candidates with Senate confirmation hurdles, including requirements for medical or scientific credentials and positions on issues like mifepristone. The 21.4% probability of no permanent announcement by year-end reflects the ongoing search timeline, acting leadership stability, and potential delays from congressional reviews ahead of midterms.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Mercado abierto: May 12, 2026, 7:59 PM ET
Volumen
$12,400Fecha de finalización
31 dic 2026Mercado abierto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads trader consensus at 42.5% as the acting FDA commissioner following Marty Makary’s May 2026 resignation, drawing support from his role as deputy commissioner for human foods, prior Jones Day regulatory work, and reported ties to the Trump family amid the administration’s “Make America Healthy Again” priorities. Sara Brenner, Brett Giroir, Grace Graham, and Stephen Hahn trail as the White House weighs candidates with Senate confirmation hurdles, including requirements for medical or scientific credentials and positions on issues like mifepristone. The 21.4% probability of no permanent announcement by year-end reflects the ongoing search timeline, acting leadership stability, and potential delays from congressional reviews ahead of midterms.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$12,400Fecha de finalización
31 dic 2026Mercado abierto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas leads trader consensus at 42.5% as the acting FDA commissioner following Marty Makary’s May 2026 resignation, drawing support from his role as deputy commissioner for human foods, prior Jones Day regulatory work, and reported ties to the Trump family amid the administration’s “Make America Healthy Again” priorities. Sara Brenner, Brett Giroir, Grace Graham, and Stephen Hahn trail as the White House weighs candidates with Senate confirmation hurdles, including requirements for medical or scientific credentials and positions on issues like mifepristone. The 21.4% probability of no permanent announcement by year-end reflects the ongoing search timeline, acting leadership stability, and potential delays from congressional reviews ahead of midterms.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes